Re: The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer

2009 ◽  
Vol 55 (6) ◽  
pp. 1488-1489 ◽  
Author(s):  
Dieter Jocham ◽  
Christian Doehn
Keyword(s):  
Prostate Cancer ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Open Label ◽  
Parallel Group ◽  
Phase Iii Study

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

2008 ◽  
Vol 102 (11) ◽  
pp. 1531-1538 ◽  
Author(s):  
Laurence Klotz ◽  
Laurent Boccon-Gibod ◽  
Neal D. Shore ◽  
Cal Andreou ◽  
Bo-Eric Persson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Open Label ◽  
Parallel Group ◽  
Phase Iii Study

DEGARELIX COMPARED TO LEUPROLIDE DEPOT 7.5 MG IN A 12- MONTH RANDOMISED, OPEN-LABEL, PARALLEL-GROUP PHASE III STUDY IN PROSTATE CANCER PATIENTS

2008 ◽  
Vol 7 (3) ◽  
pp. 205 ◽  
Author(s):  
L. Boccon-Gibod ◽  
L. Klotz ◽  
H. Schröder ◽  
C. Andreou ◽  
B.E. Persson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Phase Iii ◽  
Open Label ◽  
Parallel Group ◽  
Phase Iii Study

scholarly journals Efficacy and safety of 3-month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study

2018 ◽  
Vol 109 (6) ◽  
pp. 1920-1929 ◽  
Author(s):  
Seiichiro Ozono ◽  
Taiji Tsukamoto ◽  
Seiji Naito ◽  
Shigeo Horie ◽  
Yasuo Ohashi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Dosing Regimen ◽  
Phase Iii Study ◽  
Japanese Subjects
Sign in / Sign up

Export Citation Format

Share Document